Please complete the form below and a member of the BOTOX® team will get back to you.
Please fill in your details below only if you are a UK registered healthcare professional and would like to be contacted by an AbbVie representative.
BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency; neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic), or multiple sclerosis.1
The BOTOX® (botunlinum toxin type A) prescribing information and adverse event reporting information can be found at the bottom of the page.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/
Adverse events should also be reported to AbbVie on [email protected]
Date of preparation: December 2022. UK-BUO-220113.